Gastrointestinal Endoscopy Unit, Hospital das Clínicas, University of Sao Paulo School of Medicine, São Paulo, Brazil.
Department of Medicine, West Virginia University Health Sciences Center Charleston Division, Charleston, WV, USA.
Obes Surg. 2020 May;30(5):1971-1987. doi: 10.1007/s11695-020-04449-9.
Endoscopic sleeve gastroplasty (ESG) has emerged as a promising technique in endoscopic bariatric and metabolic therapies (EBMTs). We aimed to perform a systematic review and meta-analysis to provide an update on its efficacy and safety.
This is a systematic review and meta-analysis was performed following the PRISMA guidelines. MEDLINE, Cochrane, EMBASE, and LILACS were searched to identify the studies related to ESG.
Eleven studies with a total of 2170 patients were included. The average BMI pre-ESG was 35.78 kg/m. Pooled mean %TWL observed at 6, 12, and 18 months was 15.3%, 16.1%, and 16.8% respectively. Pooled mean %EWL at 6, 12, and 18 months was 55.8%, 60%, and 73% respectively. No procedure-related mortality was reported.
ESG is a safe and effective procedure for primary obesity therapy with promising short- and mid-term results.
内镜袖状胃成形术（ESG）已成为内镜减重和代谢治疗（EBMT）中一种很有前途的技术。我们旨在进行系统评价和荟萃分析，以提供其疗效和安全性的最新信息。
本研究按照 PRISMA 指南进行了系统评价和荟萃分析。检索 MEDLINE、Cochrane、EMBASE 和 LILACS，以确定与 ESG 相关的研究。
共纳入 11 项研究，总计 2170 例患者。ESG 前平均 BMI 为 35.78kg/m。6、12 和 18 个月时的平均 %TWL 分别为 15.3%、16.1%和 16.8%。6、12 和 18 个月时的平均 %EWL 分别为 55.8%、60%和 73%。未报告与手术相关的死亡。
ESG 是一种安全有效的原发性肥胖症治疗方法，具有良好的短期和中期效果。
